NEO New Oncology has launched NEOliquid, a non-invasive cancer diagnostics test that requires a little as 18 milliliters of blood. It identifies clinically relevant, cancer-specific point mutations, insertions, deletions, and gene fusions in circulating cell-free DNA down to an allele frequency of 0.1 percent. NEOliquid comprises 39 genes relevant for the treatment of solid tumors. It enables parallel analysis of both the primary tumor as well as its metastases, capturing the entire heterogeneity of the disease, and can be applied to reveal additional possible therapeutic options for the patient, the company said in a statement. The product is applicable to patients with solid tumors, such as lung, skin, breast, stomach, intestinal or ovarian cancer, or in childhood malignancies such as neuroblastoma.